Skip to main content
Premium Trial:

Request an Annual Quote

Affy's Clinical Services Lab Clears CLIA

NEW YORK (GenomeWeb News) - Affymetrix said today its Clinical Services Lab has been certified to begin offering microarray-based molecular diagnostic testing under Clinical Laboratory Improvement Amendments.
 
The ACSL, a 10,000 square-foot lab in Sacramento, Calif., will be used for clinical trial and patient testing, the company said. 
 
The facility's offerings include gene expression monitoring, genotyping, chromosomal copy number analysis, and other molecular diagnostic tests.
 
Affy said that the lab has already signed two agreements with customers.
 
CLIA certification ensures that the lab's processes meet standards for accuracy, precision, sensitivity, calibration, and control under federal and Clinical Laboratory Standards Institute regulations.
 
All of the lab's assays have also been validated for clinical applications, the company said.
 
Affy said the lab received the clearance on April 9.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.